BMO Capital Raises Price Target on Merck (MRK)

BMO Capital Raises Price Target on Merck (MRK)


Pharmaceutical company Merck & Co., Inc. (MRK) had its price target raised by BMO Capital on Tuesday, as the analysts believe that the company has a number of exciting drugs currently in its clinical pipeline.

The analysts maintain an “Outperform” rating on MRK and now see shares reaching $54. This price target suggests an 11% upside to Monday’s closing price of $48.45.

Merck shares were down a fraction during morning trading on Tuesday. The stock is up +18.03% year-to-date.

The Bottom Line
Shares of Merck (MRK) have a dividend yield of 3.55% based on last night’s closing price of $48.45 and the company’s annualized dividend payout of $1.72 per share.

Merck & Co., Inc. (MRK) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today